Abstract
ObjectiveLong-term extension (LTE) studies of belimumab in SLE do not include a comparator arm, preventing comparisons between belimumab plus standard therapy and standard therapy alone for organ damage accrual. Propensity...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have